Evidence map›Paper›PMID 29311660›Full record

ArticleScientific reports2018

Defining Phenotypes in Diabetic Nephropathy: a novel approach using a cross-sectional analysis of a single centre cohort.

Rosa M Montero, Athula Herath, Ashfaq Qureshi, Ehsanollah Esfandiari, Charles D Pusey, Andrew H Frankel, Frederick W K Tam

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.6field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Diabetic kidney disease, biomarkers, and finerenone.Diabetes, obesity & metabolism · 2026
    Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Rosa M MonteroRenal and Vascular Inflammation Section, Department of Medicine, Imperial College London, Hammersmith Hospital, London, W12 0NN, UK. rosa_montero@hotmail.com.ORCID http://orcid.org/0000-0003-4957-6134
Athula HerathNovartis Pharmaceuticals, GU16 7SR, Camberley, UK.
Ashfaq QureshiRenal and Vascular Inflammation Section, Department of Medicine, Imperial College London, Hammersmith Hospital, London, W12 0NN, UK.
Ehsanollah EsfandiariRenal and Vascular Inflammation Section, Department of Medicine, Imperial College London, Hammersmith Hospital, London, W12 0NN, UK.
Charles D PuseyRenal and Vascular Inflammation Section, Department of Medicine, Imperial College London, Hammersmith Hospital, London, W12 0NN, UK.
Andrew H FrankelRenal and Vascular Inflammation Section, Department of Medicine, Imperial College London, Hammersmith Hospital, London, W12 0NN, UK.
Frederick W K TamRenal and Vascular Inflammation Section, Department of Medicine, Imperial College London, Hammersmith Hospital, London, W12 0NN, UK.ORCID http://orcid.org/0000-0002-0614-9856
Hammersmith Hospital · GBKing's College London · GBNovartis (United Kingdom) · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The global increase in Diabetes Mellitus (DM) has led to an increase in DM-Chronic Kidney Disease (DM-CKD). In this cross-sectional observational study we aimed to define phenotypes for patients with DM-CKD that in future may be used to individualise treatment We report 4 DM-CKD phenotypes in 220 patients recruited from Imperial College NHS Trust clinics from 2004-2012. A robust principal component analysis (PCA) was used to statistically determine clusters with phenotypically different patients. 163 patients with complete data sets were analysed: 77 with CKD and 86 with DM-CKD. Four different clusters were identified. Phenotypes 1 and 2 are entirely composed of patients with DM-CKD and phenotypes 3 and 4 are predominantly CKD (non-DM-CKD). Phenotype 1 depicts a cardiovascular phenotype; phenotype 2: microvascular complications with advanced DM-CKD; phenotype 3: advanced CKD with less anaemia, lower weight and HbA1c; phenotype 4: hypercholesteraemic, younger, less severe CKD. We are the first group to describe different phenotypes in DM-CKD using a PCA approach. Identification of phenotypic groups illustrates the differences and similarities that occur under the umbrella term of DM-CKD providing an opportunity to study phenotypes within these groups thereby facilitating development of precision/personalised targeted medicine.

Indexed as

PhenotypeComorbidityCross-Sectional StudiesCytokinesDiabetic NephropathiesFemaleHumansInflammation MediatorsMaleNeovascularization, PathologicCytokinesInflammation Mediators

Identifiers

PMID29311660
PMCPMC5758706
OpenAlexW2782445165

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.